Table 4.

Characteristics of included patients in summary

No	Age	Gender	Baseline disease	Treatment regimen	Duration of ICU stay (day)	Microbiological response	Clinical response	Outcome
1	31	F	CIDPa	Meropenem/ampicillin-sulbactam	32	Persistent	Cure	EXP.
2	82	F	-	Meropenem/ampicillin-sulbactam	96	Persistent	Improvement	DC.
3	32	F	Cerebral hemangioblastoma	Meropenem/colistin	10	Eradication	Cure	DC
4	32	F	Metastatic breast cancer	Meropenem/ampicillin-sulbactam	105	Eradication	Improvement	EXP
5	51	M	Metastatic spinal tumor	Meropenem/ampicillin-sulbactam	47	Eradication	Cure	DC
6	53	M	Ankylosing Spondylitis	Meropenem/ampicillin-sulbactam	35	Super-infection	Improvement	EXP.
7	60	M	Gastric cancer	Meropenem/colistin	22	Intermediate	Failure	EXP.
8	65	M	CVA, HTN, Parkinson	Meropenem/colistin	49	Eradication	Cure	DC
9	79	F	HTN	Meropenem/colistin	69	Intermediate	Cure	EXP.
10	45	M	-	Meropenem/ampicillin-sulbactam	10	Intermediate	Failure	EXP.
11	49	M	IHD, DM, HTN, CVA	Meropenem/ampicillin-sulbactam	61	Intermediate	Failure	EXP.
12	65	M	IHD, CABG, DM, HTN, BPH	Meropenem/colistin	82	Eradication	Cure	DC.
13	73	M	-	Meropenem/ampicillin-sulbactam	10	Intermediate	Cure	DC.
14	79	M M	IHD, DM, CKD, CVA, Rectal carcinoma	Meropenem/ampicillin-sulbactam		Super-infection	Cure
15	65	M	Prostatic adenocarcinoma	Meropenem/ampicillin-sulbactam	39	Superinfection	Improvement	EXP.
16	80	M	CHF, MI, COPD, Alzheimer disease	Meropenem/colistin	84	Intermediate	Cure	EXP.
17	60	M	Lung transplantation	Meropenem/colistin	17	Supe-rinfection	Failure	EXP.
18	84	F	CABG, Valvular AF, COPD	Meropenem/colistin	19	Super-infection	Failure	EXP.
19	41	F	Parkinson	Meropenem/ampicillin-sulbactam		Eradication	Cure	DC.
20	67	F	CVA	Meropenem/colistin	12	Super-infection	Improvement	EXP.
21	85	M	HTN, IHD, DM, CVA	Meropenem/colistin	55	Eradication	Cure	EXP.
22	70	M	HTN, DM, BPH, hypothyroidism	Meropenem/colistin	31	Intermediate	Improvement	EXP.
23	75	M	DM, CVA	Meropenem/ampicillin-sulbactam	40	Intermediate	Improvement	DC.
24	76	M	HTN, Parkinson	Meropenem/colistin	34	Intermediate	Improvement	EXP.
25	68	M	Rectal carcinoma	Meropenem/ampicillin-sulbactam	13	Intermediate	Failure	EXP.
26	23	M	Down syndrome	Meropenem/ampicillin-sulbactam	93	Eradication	Cure	DC.
27	17	F	-	Meropenem/colistin	12	Intermediate	Cure	DC.
28	68	M	HTN, DM, CVA	Meropenem/colistin	32	Persistent	Cure	EXP.
29	41		-	Meropenem/colistin	11	Eradication	Cure	DC.

DM, diabetes mellitus; CHD, chronic heart disease; IHD, ischemic heart disease; HTN, hypertension; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CVA, cerebrovascular accident; CIDP, chronic inflammatory demyelinating polyneuropathy; MI, myocardial ischemia; CABG, coronary artery bypass graft; BPH, benign prostatic hyperplasia; EXP, expired; DC, discharged.